

OnCore Protocol Naming Conventions

Protocol Name is limited to 25 characters

There can be no blank spaces in a name

The only allowable non-alphanumeric character is a dash (-)

Cancer Center Research Managers and OnCore Support are currently the only users who can put in a New Protocol and therefore enter protocol names. They should follow these guidelines:

Cancer Center Naming:

- **Pharmacy/Industry Trials:** Drug Company Name-Sponsor Protocol Name, e.g. MERCK-055
 - Company names may be shortened due to space limitations, for example AstraZeneca as AZ.
 - Where multiple sponsors, use the funding sponsor in the name.
- **Cooperative Group:** Group Name-Sponsor Protocol Name, e.g. ALLIANCE-A011203.
- **Foundation Trials** – Pharmacy/Industry trials that are opened in collaboration with or requiring membership in a cooperative group/consortium: Group Name-Sponsor Protocol Name, e.g. COG-AAML1321. Please review OnCore Communication Memo #25 – Foundation Trials Sponsor Designation.
- **Consortium Trials** – Pharmacy/Industry trials that are open in collaboration with or requiring membership in a consortium group: Drug Company Name-Sponsor Protocol Name-Consortium Name or initials, e.g. BERG-15-022.
- **Investigator-Initiated Trials:** IIT-PI Last Name-Commonly Used Protocol Name, e.g. IIT-ATALLAH-LAST-TKI.
- **External Investigator-Initiated Trials** – IIT (institutional) studies from other colleges/hospitals opened at MCW/Froedtert/CHW, where the external site is the coordinating center: Center name or initials-Protocol or Commonly Used Name, e.g. UMICH-ANTI-PD-1.
- **Expanded Access Trials** – Facilitates access to drugs or devices where the subject(s) may not be eligible to go on a trial but could benefit from the therapeutic option: EXPACC-Drug Company Name-Sponsor Protocol Name, e.g. EXPACC-JANSSEN-SAR-3002.
- **Treatment Use Only Trials (Compassionate Use Trials)** – Subject(s) who were enrolled on a study are given IRB permission to continue to use the study drug(s) even though they have gone off-study: TXUSE-Drug Company Name-Sponsor Protocol Name, e.g. TXUSE-GLOBE-G14000-14.
- **Emergency Investigative Drug or Device Use Trials** – Subject(s) are given IRB permission to emergently use an experimental therapeutic option, not on-study, for a particular disease/diagnosis/symptom: E-IND-Drug Company Name-Drug Name, e.g. E-IND-ANSUN-DAS181.

Non-Cancer Naming:

- Non-cancer studies will follow the same guidelines as above, with the exception that they will add their Department/Division as a prefix to the Protocol Name. Prefixes are as follows (below). This list will be updated as new Departments/Divisions start to use OnCore.

• Pulmonary - PULM	• Cardiovascular – CVC
• Nephrology – NEPH	• Gastrointestinal - GI
• Infectious Disease – INF	• Endocrinology – ENDO
• Ophthalmology – OPH	• Department of Surgery – SURG
• Department of Neurology – NEURO	• OB/GYN Non-oncology – OBG
• GIM – General Internal Medicine	• Pediatric non-cancer studies should use the same division names as adult but add a P- as a prefix to the prefix.
• Herma Heart Institute -HHI	